

Peer Review File

Article Information: <https://dx.doi.org/10.21037/tlcr-24-63>

Reviewer A

Nice state of art

Reply: I thank the Reviewer A for the comment.

Reviewer B

The Author submitted a commentary on the subcutaneous administration of immune-checkpoint inhibitors.

The topic is clearly presented and discussed, highlighting both pros and cons. The use of English language is fine and the table is helpful in presenting ongoing clinical trials.

I definitely appreciate the discussion of the pharmacoeconomics aftermath, given the forthcoming availability of ICI biosimilars.

I do not have revisions to suggest.

Reply: I appreciate the positive comments.